| 摘要: |
| 目的：探讨参麦注射液对非小细胞肺癌生存期的影响。方法：纳入扬中市2020—2022年符合标准的非小细胞肺癌死亡病例进行回顾性研究，根据治疗情况分为对照组69 例（单采用西医治疗）、参麦组127 例（在西医治疗的基础上联合参麦注射液治疗）。通过倾向性评分匹配后得出对照组47例，参麦组47 例。应用COX回归模型分析肺癌患者生存期的影响因素，采用Kaplan-Meier法及Log-rank比较倾向性评分匹配前后2组的总生存期（overall survival，OS）。结果：“参麦注射液联合治疗”“化疗”“靶向治疗”为肺癌患者的独立保护因素。与对照组比较，参麦组能显著延长中位OS（P＜0.05），对于Ⅳ期、生存期不足3年的非小细胞肺癌患者，参麦注射液联合免疫治疗及斑蝥酸钠治疗能延长生存时间。结论：参麦注射液联合西医治疗能延长患者OS，且联合免疫治疗在晚期非小细胞肺癌上获益更明显。 |
| 关键词: 非小细胞肺癌 参麦注射液 生存期 回顾性研究 倾向性评分匹配 免疫治疗 |
| DOI： |
|
|
| Effect of Shenmai injection on the survival time of non-small cell lung cancer：A retrospective study |
| QIN Lei,ZHANG Xiaochun |
| (School of Clinical Chinese Medicine，Yangzhou University，Yangzhou 225001，Jiangsu，China) |
| Abstract: |
| Objective：To investigate the effect of Shenmai injection on the survival time of non-small cell lung cancer (NSCLC).Methods：A retrospective study was performed for the death cases of NSCLC meeting related criteria in Yangzhong from 2020 to 2022，and according to the treatment modality，the patients were divided into control group with 69 patients (Western medicine treatment alone) and Shenmai group with 127 patients (Shenmai injection in addition to Western medicine treatment).After propensity score matching (PSM)，there were 47 patients in each group.The Cox regression model was used to investigate the influencing factors for survival time，and the Kaplan-Meier analysis and the log-rank test were used for comparison of overall survival (OS) between the two groups before and after PSM.Results：Combined treatment with Shenmai injection，chemotherapy，and targeted therapy were independent protective factors for patients with lung cancer.Compared with the control group，〖JP2〗Shenmai injection significantly prolonged median OS (P＜0.05)，and for stage Ⅳ NSCLC patients with a survival time of ＜3 years，Shenmai injection combined with immunotherapy and sodium cantharidate could prolong survival time.Conclusion：Shenmai injection combined with Western medicine treatment can prolong the OS of patients，with more significant benefits for advanced NSCLC when combined with immunotherapy. |
| Key words: non-small cell lung cancer Shenmai injection survival time retrospective study propensity score matching immunotherapy |
